For Healthcare Professionals

Study of Efficacy and Safety of Ofatumumab in Relapsing Multiple Sclerosis (RMS) Patients in China


About the study

The purpose of this study is to evaluate the efficacy and safety of ofatumumab s.c. in adult participants with relapsing multiple sclerosis (RMS) in China.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Inclusion Criteria:

Male or female Chinese aged 18-55 years (inclusive) at their enrollment of the study (signing the study consent form).

Clinical definite diagnosis of RMS according to the 2017 Revised McDonald criteria (Thompson et al 2018, and the documentation prior to their enrollment to the study (signing the study consent form) of:

  1. Two documented relapses during the past 2 years, or
  2. One documented relapse during the last year, or
  3. A positive Gd-enhancing MRI scan during the year prior to Screening. Note: Screening MRI scan may be used if no positive Gd-enhancing scan exists from prior year.
  4. Disability status with an EDSS score of 0 - 5.5 (inclusive) at Screening.
  5. Neurologically stable within 1 month prior to both Screening and Baseline (including no MS relapse in this period).


Exclusion Criteria:

  1. Participants with primary progressive MS (PPMS) or secondary progressive MS (SPMS) without disease activity
  2. Participants meeting criteria for neuromyelitis optica spectrum disorder (NMOSD)
  3. Pregnant or nursing (lactating) women
  4. Women of child-bearing potential unless using effective methods of contraception while taking study treatment and for at least 6 months after stopping medication
  5. Participants with an active chronic disease of the immune system other than MS
  6. Participants with neurological findings consistent with PML or confirmed PML
  7. Participants with active hepatitis B disease
  8. Participants with active systemic infections (including but not limited to active COVID-19 infection) or known to have AIDS or to test positive for HIV antibody at Screening
  9. Participants at high risk of developing or having reactivation of syphilis or tuberculosis
  10. Have received any live or live-attenuated vaccines within four weeks prior to first study drug administration
  11. Have been treated with medications as specified or within timeframes specified in the protocol
  12. Any other disease or condition that could interfere with participation in the study according to the study protocol, or with the ability of the participants to cooperate and comply with the study procedures.

Other protocol-defined inclusion/exclusion criteria may apply.

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Study’s details


Relapsing Multiple Sclerosis

Age (in years)

18 - 55


Phase 4

Participants needed


Est. Completion Date

Aug 19, 2025

Treatment type



Novartis identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.